沃森生物
(300142)
| 流通市值：221.76亿 | | | 总市值：227.28亿 |
| 流通股本：15.68亿 | | | 总股本：16.07亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 599,753,563.65 | 4,113,772,327.17 | 3,158,044,365.35 | 2,167,671,315.8 |
| 营业收入 | 599,753,563.65 | 4,113,772,327.17 | 3,158,044,365.35 | 2,167,671,315.8 |
| 二、营业总成本 | 462,149,769.99 | 3,152,213,298.29 | 2,320,868,365.21 | 1,526,144,421.03 |
| 营业成本 | 113,518,843.35 | 597,556,154.05 | 451,263,592.53 | 272,566,663.71 |
| 税金及附加 | 4,173,429.23 | 32,025,953.23 | 25,372,739.36 | 19,712,500.19 |
| 销售费用 | 210,455,707.93 | 1,519,575,535.5 | 1,143,352,423.64 | 783,046,486.73 |
| 管理费用 | 61,785,575.99 | 297,623,740.18 | 180,626,471.22 | 120,895,385.47 |
| 研发费用 | 87,020,581.52 | 776,425,262.92 | 573,442,296.5 | 365,185,867.18 |
| 财务费用 | -14,804,368.03 | -70,993,347.59 | -53,189,158.04 | -35,262,482.25 |
| 其中:利息费用 | 3,381,948.43 | 5,948,806.93 | 3,756,740.94 | 2,723,941.26 |
| 其中:利息收入 | 18,310,787.16 | 74,232,699.53 | 52,659,002.45 | 36,258,268.92 |
| 加:公允价值变动收益 | -84,817,900 | -234,750,100 | -67,388,900 | -17,652,900 |
| 加:投资收益 | 86,840.07 | 7,114,472.14 | 6,294,623.82 | 6,328,364.21 |
| 资产处置收益 | - | -827,732.05 | -574,864.06 | 172,214.11 |
| 资产减值损失(新) | -7,606,338.91 | -162,640,206.44 | -12,571,870.97 | -3,591,714.41 |
| 信用减值损失(新) | -9,893,290.24 | -88,519,479.82 | -67,083,381.2 | -60,676,183.54 |
| 其他收益 | 24,276,049.91 | 132,030,165.54 | 83,460,038.36 | 65,948,796.8 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 59,649,154.49 | 613,966,148.25 | 779,311,646.09 | 632,055,471.94 |
| 加:营业外收入 | 101.88 | 935,055.64 | 933,183.65 | 913,181.97 |
| 减:营业外支出 | 2,396,025.76 | 15,924,716.59 | 6,023,773.53 | 4,944,894.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 57,253,230.61 | 598,976,487.3 | 774,221,056.21 | 628,023,759.87 |
| 减:所得税费用 | 18,941,003.7 | 87,651,389.31 | 76,991,654.32 | 65,474,626.49 |
| 六、净利润 | 38,312,226.91 | 511,325,097.99 | 697,229,401.89 | 562,549,133.38 |
| 持续经营净利润 | 38,312,226.91 | 511,325,097.99 | 697,229,401.89 | 562,549,133.38 |
| 归属于母公司股东的净利润 | 14,127,534.12 | 419,390,211.2 | 553,376,456.49 | 455,239,815.96 |
| 少数股东损益 | 24,184,692.79 | 91,934,886.79 | 143,852,945.4 | 107,309,317.42 |
| (一)基本每股收益 | 0.01 | 0.26 | 0.35 | 0.28 |
| (二)稀释每股收益 | 0.01 | 0.26 | 0.35 | 0.28 |
| 九、综合收益总额 | 38,312,226.91 | 511,325,097.99 | 697,229,401.89 | 562,549,133.38 |
| 归属于母公司股东的综合收益总额 | 14,127,534.12 | 419,390,211.2 | 553,376,456.49 | 455,239,815.96 |
| 归属于少数股东的综合收益总额 | 24,184,692.79 | 91,934,886.79 | 143,852,945.4 | 107,309,317.42 |
| 公告日期 | 2024-04-25 | 2024-03-30 | 2023-10-26 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |